Podcasts about ADC

Do you think the ADC coalition would thrive without any state governor in its ranks?Ponsah Fanap and Joseph Gilbert would be having a with Santos Ayuba Larabs Tanshak (SALT) on the issues.

Political Shift: The wave in the ADC has no doubt shocked the nation with lots of people leaving their political parties to join the coalition.The coalition which involves members of various political parties in Nigeria is looking forward to rescue Nigeria from the current administration.The recent collapse of the PDP structure in Yobe state also came a shocker leaving just the Acting National Chairman of the PDP as the member of the party.With the latest influx being witnessed in the coalition, should the present administration be threatened?Let's Talk will be live as Richard Badung hosts, Barr Titilope AnifowosheLawyer| Executive Director, Eagles Foundation for Humanity 

Send us a textPeaches and Aaron are back swinging at the nonsense. From Special Warfare's assessment model to Air Force Academy cadets racking up predatory loans, this episode rips into leadership fails, lazy commanders who hand out paperwork like candy, and the lost art of spot corrections. We go from stories of LOCs, LORs, and mustache games with Rangers, to watching Army football drop a quarter million dollars just to get smoked by Tarleton State. Oh, and Peaches gets dragged through camp in just a towel because Rangers can't handle beards. Add in college football meltdowns, fantasy league punishments, and some blistering hot takes on what “leadership” actually means—you've got a mix of cringe, comedy, and brutal honesty that only Ones Ready delivers.⏱️ Timestamps: 00:00 – Intro & Special Warfare assessment truth bombs 01:15 – Operator Training Summit Nashville & gear talk 03:10 – Booties in the pool: stop training slick 04:45 – AOCs gone wild with paperwork 07:00 – Progressive discipline vs lazy leadership 10:20 – Why real mentorship beats LOR inflation 12:50 – Spot corrections, life problems, and actually helping airmen 17:30 – Setting boundaries and predictable leadership 23:10 – Smoke sessions, “don't tell dad,” and better discipline tools 25:30 – Peaches' LOC story that turned his career around 29:30 – Pushing boundaries vs working the system 33:00 – Rangers, beards, and the towel walk of shame 36:00 – Mustache game rules and how to win (or lose) 40:00 – Always rebuttal your paperwork (and call ADC, not your buddy) 41:30 – The insane $416K Academy disenrollment bill 47:00 – The infamous Manitou Incline & OTS candidate pain fest 54:00 – Army football pays $250K to lose to Tarleton State 56:10 – Air Force uniforms: actually fire this year 01:02:00 – Bama gets stomped, SEC fan tears taste delicious 01:03:50 – Peaches unveils the Fantasy Loser Belt 01:04:55 – Wrap up & call-to-actions

Featuring an interview with Dr Jacob Sands, including the following topics: Management of Adverse Events of Special Interest Associated with Datopotamab Deruxtecan (Dato-DXd) (0:00) Heist RS et al. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev 2024;125:102720. Abstract  Sands J et al. Analysis of drug-related interstitial lung disease (ILD) in patients (pts) treated with datopotamab deruxtecan (Dato-DXd). ASCO 2024;Abstract 8623. Intracranial Efficacy of Dato-DXd for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Actionable Genomic Alterations in the TROPION-Lung05 Study (7:23) Lisberg A et al. Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05. ASCO 2024;Abstract 8593.  Clinical Evidence Supporting the Combination of Dato-DXd with Immune Checkpoint Inhibition for Advanced NSCLC (12:12) Bessede A et al. TROP2 is associated with primary resistance to immune checkpoint inhibition in patients with advanced non-small cell lung cancer. Clin Cancer Res 2024;30(4):779-85. Abstract Levy BP et al. TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC). ASCO 2025;Abstract 8501. Waqar SN et al. First-line (1L) datopotamab deruxtecan (Dato-DXd) + rilvegostomig in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohort 5). ASCO 2025;Abstract 8521. Current and Future Development of Antibody-Drug Conjugates in the Treatment of Lung Cancer (17:11) Tawfiq RK et al. Targeting lung cancer with precision: The ADC therapeutic revolution. Curr Oncol Rep 2025;27(6):669-86. Abstract CME information and select publications

In this podcast, experts Aditya Bardia, MD, MPH, FASCO; and Erika P. Hamilton, MD, discuss recent efficacy and safety data of TROP2-targeted antibody-drug conjugate (ADC) plus immune checkpoint inhibitor combinations for advanced triple-negative breast cancer (TNBC).

Have you ever felt the presence of a loved one after they passed? Was it just your imagination… or could it have been a sacred message from the other side? In this soul-stirring episode of The Abundance Journey, Elaine welcomes the radiant and deeply wise Purnima Sinha, a wellness and spiritual life coach with over 50 years of meditation practice and profound experience in after-death communication, mystical encounters, and soul-to-soul connection. Together, Elaine and Purnima explore:· How to recognize signs and messages from loved ones who have crossed over· Why intention and energy are the keys to unlocking Divine guidance· The role of self-love, forgiveness, and surrender in profound healing· How grief, loss, and even pain can become portals to spiritual connection and abundance This conversation will remind you that love never dies, that you are always supported, and that the Divine is inviting you into a deeper partnership with every breath. About the Guest:(bio, personal links, resource links)Purnima has been trained in Ultra Transcendental Meditation- Surat Shabd Yoga. Purnima practiced meditation for over 50 years. Purnima does private sessions. Purnima has Certificates in LifeStyle Medicine and Meditation & Psychotherapy from the Harvard School of Medicine in Boston. Purnima has presented in IANDS conference a few times and is part of Healing Circle also.Purnima has worked in the healthcare system and county wellness program since 2009 as a Wellness and Meditation/Spiritual Life Coach. Purnima has ADC, OBE, STE, Mystical experiences and shared death experiences all her life. Purnima has helped many patients during their transition. She has been interviewed by JeffMara podcast about after-death communication and an IANDS podcast by Betty Guadagno about ADC how to Let Go Finally. Purnima's article got published in Eckhart Tolle (Power Of NOW and A New Earth) newsletter about healing.Her motto is Self Care = Self LoveAbout the Host, Elaine Starling: (bio, personal links, resource links)An international TEDx speaker, bestselling author, coach and mentor, Elaine Starling is recognized for her video show and podcast, The Abundance Journey. Known as The Abundance Ambassador, Elaine helps high-achieving women stop proving and start receiving by aligning with Divine guidance. Through her coaching, podcast, and The Soul Aligned Life Process™, Elaine empowers women to embody their worth, speak their truth, and create deeply fulfilling relationships—from the inside out.Elaine Starling Social Media Links:Facebook: https://www.facebook.com/elaine.abundance Linkedin: https://www.linkedin.com/in/elainestarling/YouTube: https://www.youtube.com/channel/UC3eXgwdMYYzLicCEcB1DdrgTEDx Talk, “Abundance Is a Choice” https://youtu.be/tMQ0D4sfEysWebsite: www.TheAbundanceJourney.com5 Steps to Activate Your Abundance Universal Book Link:

In this special WCLC 2025 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss highlights from the conference. Dr. Susan Scott discusses EGFR mutant NSCLC and results from PALOMA-2 and subcutaneous amivantamab. Dr. Wenfeng Fang discusses Iza-Bren (BL-D01D1), a first-in-class EGFR x HER-3 biospecific ADC linked to a novel topoisomerase I inhibitor payload, with promising preliminary activity in EGFR positive previously treated NSCLC. Dr. Biagio Ricciuti shares his insights from WCLC 2025, including the FLAURA-2 OS readout, the HARMONi trial in EGFR positive NSCLC, and his research in the use of immunotherapy in early-stage lung cancer.

@phoenix_agenda and @nigeriasbest had a one to one chat after a long summer break.They discussed:1. President Tinubu's trips to Brazil and Japan.2. Wike says Rivers State of Emergency should end 18th September 3. INEC begins Continuous Voter Registration exercise4. President Tinubu goes to Europe on 10 day Annual Leave 5. Attack on Gbadebo Rhodes-Vivour's defection ceremony to ADC

Dr. Pedro Barata and Dr. Rana McKay discuss the integration of innovative advances in molecular imaging and therapeutics to personalize treatment for patients with renal cell and urothelial carcinomas. TRANSCRIPT Dr. Pedro Barata: Hello, I'm Dr. Pedro Barata, your guest host of By the Book, a podcast series featuring insightful conversations between authors and editors of the ASCO Educational Book. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also an associate editor of the ASCO Educational Book. Now, we all know the field of genitourinary cancers (GU) is evolving quite rapidly, and we have new innovations in molecular imaging as well as targeted therapeutics. Today's episode will be exploring novel approaches that are transforming the management of renal cell and urothelial carcinomas and also their potential to offer a more personalized treatment to patients. For that, joining for today's discussion is Dr. Rana McKay, a GU medical oncologist and professor at University of California San Diego. Dr. McKay will discuss her recently published article titled, “Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas.”  Our full disclosures are available in the transcript of this episode.  And with that, Rana McKay, great to have you on the podcast today. Dr. Rana McKay: Oh, thank you so much, Dr. Barata. It's really wonderful to be here with you. So, thanks for hosting. Dr. Pedro Barata: No, thanks for taking the time, and I'm looking forward to this conversation. And by the way, let me start by saying congrats on a great article in the Educational Book. Really super helpful paper. I'm recommending it to a lot of the residents and fellows at my own institution. I would like to first ask you to kind of give our listeners some context of how novel approaches in the molecular imaging as well as targeted therapeutics are actually changing the way we're managing patients with GU, but specifically with renal cell carcinoma and urothelial carcinoma. So, what are the areas you would call out as like being big areas for innovation in this context, and why are they important? Dr. Rana McKay: Very good question. And I think this is really what this article highlights. It highlights where are we going from an imaging diagnostics standpoint? Where are we going from a therapeutic standpoint? And I think if we have to step back, from the standpoint of diagnostics, we've seen PET imaging really transform diagnostics in prostate cancer with the advent of PSMA PET imaging, and now PSMA PET imaging is used as a biomarker for selection for theranostics therapy. And so, we're starting to see that enter into the RCC landscape, enter into the urothelial cancer landscape to a lesser extent. And I think it's going to potentially be transformative as these tools get more refined. I think when we think about therapeutics, what's been transformative most recently in the renal cell carcinoma landscape has been the advent of HIF2α inhibition to improve outcomes for patients. And we have seen the approval of belzutifan most recently that has reshaped the landscape. And now there's other HIF2α inhibitors that are being developed that are going to be further important as they get refined. And lastly, I think when we think about urothelial carcinoma, the greatest transformation to treatment in that context has been the displacement of cisplatin and platinum-based chemotherapy as a frontline standard with the combination of enfortumab vedotin plus pembrolizumab. And we've seen antibody-drug conjugates really reshape treatment and tremendously improve outcomes for patients. So, I think those are the three key areas of interest. Dr. Pedro Barata: So with that, let's focus first on the imaging and then we'll get to the therapeutic area. So, we know there's been a paradigm shift, really, when prostate-specific targets emerged as tracers for PET scanning. And so, we now commonly use prostate-specific membrane antigen, or PSMA-based PET scanning, and really transform how we manage prostate cancer. Now, it appears that we're kind of seeing a similar wave in renal cell carcinoma with the new radiotracer against the target carbonic anhydrase IX. What can you tell us about this? And is this going to be available to us anytime soon? And how do you think that might potentially change the way we're managing patients with RCC today? Dr. Rana McKay: First, I'll step back and say that in the context of PSMA PET imaging, we have actually been able to better understand RCC as well. So, we know that PSMA is expressed in the neovasculature of tumors, and it can actually be used to detect renal cell carcinoma tumors. It has a detection rate of about 84% when used for detection. And so, you know, I don't think it's just restricted to carbonic anhydrase IX, but we will talk about that. So, PSMA expressed in the neovasculature has a detection rate of around 84%, particularly if we're looking at clear cell RCC. CAlX is overexpressed in clear cell RCC, and it's actually used in diagnosing renal cell carcinoma when we think of CAlX IHC for diagnosing clear cell RCC. And now there are CAlX PET tracers. The first foray was with the ZIRCON study that was actually an interestingly designed study because it was designed to detect the likelihood of PET imaging to identify clear cell RCC. So, it was actually used in the early diagnostics setting when somebody presents with a renal mass to discriminate that renal mass from a clear cell versus a non-clear cell, and it was a positive study. But when I think about the potential application for these agents, you know, I think about the entire landscape of renal cell carcinoma. This is a disease that we do treat with metastasis-directed therapy. We have certainly seen patients who've undergone metastasectomy have long, durable remissions from such an approach. And I think if we can detect very early onset oligometastatic disease where a metastasis-directed therapy or SABR could be introduced - obviously tested in a trial to demonstrate its efficacy - I think it could potentially be transformative. Dr. Pedro Barata: Wonderful. It's a great summary, and I should highlight you are involved in some of those ongoing studies testing the performance of this specific PET scanning for RCC against conventional imaging, right? And to remind the listeners, thus far, for the most part, we don't really do FDG-PET for RCC. There are some specific cases we do, but in general, they're not a standard scanning. But maybe that will change in the future. Maybe RCC will have their own PSMA-PET. And to your point, there's also emerging data about the role of PSMA-PET scanning in RCC as well, as you very elegantly summarized. Wonderful. So, let me shift gears a little bit because you did, in your introduction, you did highlight a novel MOA that we have in renal cell carcinoma, approved for use, initially for VHL disease, and after that for sporadic clear cell renal cell carcinoma. We're talking about hypoxia-inducible factor 2-alpha inhibitors, or HIF2α inhibitors, such as belzutifan. But there's also others coming up. So, as a way to kind of summarize that, what can you tell us about this breakthrough in terms of therapeutic class, this MOA that got to our toolbox of options for patients with advanced RCC? Tell us a little bit what is being utilized currently in the management of advanced RCC. And where do you see the future going, as far as, is it moving early on? Is it getting monotherapy versus combinations? Maybe other therapies? What are your thoughts about that? What can you tell us about it? Dr. Rana McKay: Belzutifan is a first-in-class HIF2α inhibitor that really established clinical validation for HIF2α as a therapeutic target. When we think about the activity of this agent, the pivotal LITESPARK-005 trial really led to the approval of belzutifan in patients who were really heavily pretreated. It was patients who had received prior IO therapy, patients who had received prior VEGF-targeted therapy. And in the context of this study, we saw a median PFS of 5.6 months, and there did seem to be a tail on the curve when you looked at the 12-month PFS rate with belzutifan. It was 33.7% compared to 17.6% with everolimus. And then when we look at the response rate, it was higher with belzutifan on the order of 22-23%, and very low with everolimus, as we've previously seen. I think one of the Achilles heels of this regimen is the primary PD rate, which was 34% when used in later line. There are multiple studies that are testing belzutifan in combination across the treatment landscape. So, we have LITESPARK-011, which is looking at the combination of belzutifan plus lenvatinib in the second-line setting. We've got the MK-012 [LITESPARK-012] study, which is looking at belzutifan in various combinations in the frontline setting. So there is a combination with IO plus belzutifan. And so this is also being looked at in that context. And then we also have the LITESPARK-022 study, which is looking at pembrolizumab with belzutifan in the adjuvant setting. So there's a series of studies that will be exploring belzutifan really across the treatment landscape. Many of these studies in combination. Additionally, there are other HIF2α inhibitors that are being developed. We have casdatifan, which is another very potent HIF2α inhibitor. You know, I think pharmacologically, these are different agents. There's a different half-life, different dosing. What is going to be the recommended phase 3 dose for both agents, the EPO suppression levels, the degree of EPO suppression, and sustainability of EPO suppression is very different. So, I think we've seen data from casdatifan from the ARC-20 trial from monotherapy with a respectable response rate, over 30%, primary PD rate hovering just around 10%.  And then we've also seen data of the combination of casdatifan with cabozantinib as well that were recently presented this year. And that agent is also being tested across the spectrum of RCC. It's being looked at in combination with cabozantinib in the PEAK-1 study, and actually just at the KCRS (Kidney Cancer Research Summit), we saw the unveiling of the eVOLVE-RCC trial, which is going to be looking at a volrustomig, which is a PD-1/CTLA-4 inhibitor plus casdatifan compared to nivo-ipi in the frontline setting.  So, we're going to see some competition in this space of the HIF2α inhibitors. I think when we think of mechanism of action in that these are very potent, not a lot of off-target activity, and they target a driver mutation in the disease. And that driver mutation happens very early in the pathogenesis. These are going to be positioned much earlier in the treatment landscape. Dr. Pedro Barata: All these studies, as you're saying, look really promising. And when we talk about them, you mentioned a lot of combinations. And to me, when I think of these agents, it makes a lot of sense to combine because there's not a lot of overlapping toxicities, if you will. But perhaps for some of our listeners, who have not used HIF2α inhibitors in practice yet, and they might be thinking about that, what can you tell us about the safety profile? How do you present it to your patients, and how do you handle things like hypoxia or anemia? How do you walk through the safety profile and tolerability profile of those agents like belzutifan? Dr. Rana McKay: I think these drugs are very different than your traditional TKIs, and they don't cause the classic symptoms that are associated with traditional TKIs that many of us are very familiar with like the rash, hand-foot syndrome, hypertension, diarrhea. And honestly, these are very nuanced symptoms that patients really struggle with the chronicity of being on a chronic daily TKI. The three key side effects that I warn patients about with HIF2α inhibitors are: (1) fatigue; (2) anemia; and (3) hypoxia and dysregulation in the ability to sense oxygen levels. And so, many of these side effects - actually, all of them - are very dose-dependent. They can be very well-managed. So, we can start off with the anemia. I think it's critically important before you even start somebody on belzutifan that you are optimizing their hemoglobin and bone marrow function. Make sure they don't have an underlying iron deficiency anemia. Make sure they don't have B12 or folate deficiency. Check for these parameters. Many patients who have kidney cancer may have some hematuria, other things where there could be some low-level blood loss. So, make sure that those are resolved or you're at least addressing them and supplementing people appropriately. I monitor anemia very closely every 3 to 4 weeks, at least, when people start on these medications. And I do initiate EPO, erythropoietin, should the anemia start to worsen. And I typically use a threshold of around 10g/dL  for implementing utilization of an EPO agent, and that's been done very safely in the context of the early studies and phase 3 studies as well. Now, with regards to the hypoxia, I think it's also important to make sure that you're selecting the appropriate individual for this treatment. People who have underlying COPD, or even those individuals who have just a very high burden of disease in their lung, lymphangitic spread, pleural effusions, maybe they're already on oxygen - that's not an ideal candidate for belzutifan. Something that very easily can be done in the clinic before you think about initiating somebody on this treatment, and has certainly been integrated into some of the trials, is just a 6-minute walk test. You know, have the patient walk around the clinic with one of the MAs, one of the nurses, put the O2 sat on [measuring oxygen saturation], make sure they're doing okay. But these side effects, like I said, are very dose-dependent. Typically, if a patient requires, if the symptoms are severe, the therapy can be discontinued and dose reduced. The standing dose is 120 mg daily, and there's two dose reductions to 80 mg and 40 mg should somebody warrant that dose modification. Dr. Pedro Barata: This is relatively new, right? Like, it was not that we're used to checking oxygen levels, right? In general, we're treating these patients, so I certainly think there's a learning curve there, and some of the points that you highlight are truly critical. And I do share many of those as well in our practice. Since I have you, I want to make sure we touch base on antibody-drug conjugates as well. It's also been a hot area, a lot of developments there. When I think of urothelial carcinoma and renal cell carcinoma, I see it a little bit different. I think perhaps in urothelial carcinoma, antibody-drug conjugates, or ADCs, are somewhat established already. You already mentioned enfortumab vedotin. I might ask you to expand a little bit on that. And then in renal cell carcinoma, we have some ADCs as well that you include in your chapter, and that I would like you to tell us what's coming from that perspective. So, tell us a little bit about how do you see ADCs in general for GU tumors, particularly UC and RCC? Tell us a little bit about the complexity or perhaps the challenges you still see. At the same time, tell us about the successes. Dr. Rana McKay: Stepping back, let's just talk about like the principles and design of ADCs. So, most ADCs have three components. There's a monoclonal antibody that typically targets a cell surface antigen, which is conjugated by a linker, which is the second component, to a payload drug. And typically, that payload drug has been chemotherapy, whether it be topoisomerase or whether it be MMAE or other chemotherapeutic. We can start in the RCC space. There's been multiple antibody-drug conjugates that have been tested. There's antibody-drug conjugates to CD70, which is expressed on clear cell RCC. There's been antibody-drug conjugates to ENPP3, which is also expressed on RCC. There's antibody-drug conjugates to CDH6. And they have different payloads, like I said, whether it be topoisomerase I or other microtubule inhibitors. Now, when we think about kidney cancer, we don't treat this disease with chemotherapy. This disease is treated with immunotherapy. It is treated with treatments that target the VEGF pathway and historically has not been sensitive to chemo. So, I think even though the targets have been very exciting, we've seen very underwhelming data regarding activity, and in some context, seen increased toxicity with the ADCs. So, I think we need to tread lightly in the context of the integration and the testing of ADCs in RCC. We just came back from the KCRS meeting, and there was some very intriguing data about a c-Kit ADC that's being developed for chromophobe RCC, which is, you know, a huge unmet need, these variant tumors that really lack appropriate therapeutics. But I just caution us to tread lightly around how can we optimize the payload to make sure that the tumor that we're treating is actually sensitive to the agent that's targeting the cell kill. So, that's a little bit on the ADCs in RCC. I still think we have a long way to go and still in early testing. Now, ADCs for UC are now the standard of care. I think the prototypical agent, enfortumab vedotin, is a nectin-4-directed ADC that's conjugated to an MMAE payload and was the first ADC approved for advanced urothelial, received accelerated approval following the EV-201 trial, which was basically a multicenter, single-arm study that was investigating EV in cisplatin-ineligible patients with advanced urothelial carcinoma, and then ultimately confirmed in the EV-301 study as well. And so, that study ended up demonstrating the support superiority of EV from an overall survival standpoint, even PFS standpoint. Building on that backbone is the EV-302 study, which tested EV in combination with pembrolizumab versus platinum-based chemotherapy in the frontline setting. And that was a pivotal, landmark study that, like I said, has displaced platinum therapy as a frontline treatment for people with advanced urothelial carcinoma. And when we think about that study and the median overall survival and just how far we've come in urothelial cancer, the median OS with EV-pembro from that trial was 31 and a half months. I mean, that's just incredible. The control arm survival was 16 and a half months. The hazard ratio for OS, 0.47. I mean this is why when this data was presented, it was literally a standing ovation that lasted for several minutes because we just haven't seen data that have looked that good. And there are other antibody-drug conjugates that are being tested. We've all been involved in the saga with sacituzumab govitecan, which is a trophoblast cell surface antigen 2 (Trop-2) targeted ADC with a topoisomerase I payload. It was the second ADC to receive approval, but then that approval was subsequently withdrawn when the confirmatory phase 3 was negative, the TROPiCS-04 trial. So, approval was granted based off of the TROPHY-U-01, single-arm, phase 2 study, demonstrating a response rate of around 28% and a PFS of, you know, about 5 and a half months. But then failure to show any benefit from an OS standpoint. And I think there's a lot of controversy in the field around whether this agent still has a role in advanced urothelial carcinoma. And I think particularly for individuals who do not have molecular targets, like they're not HER2-amplified or have HER2-positivity or FGFR or other things like that. Dr. Pedro Barata: Fantastic summary, Rana. You were talking about the EV, and it came to mind that it might not be over, right, for the number of ADCs we use in clinical practice in the near future. I mean, we've seen very promising data for ADC against the HER2, right, and over-expression. It also can create some challenges, right, in the clinics because we're asking to test for HER2 expression. It's almost like, it's not exactly the same to do it in breast cancer, but it looks one more time that we're a little bit behind the breast cancer field in a lot of angles. And also has vedotin as a payload. Of course, I'm referring to disitamab vedotin, and there's very elegant data described by you in your review chapter as well. And it's going to be very interesting to see how we sequence the different ADCs, to your point as well. So, before we wrap it up, I just want to give you the opportunity to tell us if there's any area that we have not touched, any take-home points you'd like to bring up for our listeners before we call it a day. Dr. Rana McKay: Thank you so much. I have to say, you know, I was so excited at ASCO this year looking at the GU program. It was fantastic to see the progress being made, novel therapeutics that really there's a tremendous excitement about, not just in RCC and in UC, but also in prostate cancer, thinking about the integration of therapies, not just for people with refractory disease that, even though our goal is to improve survival, our likelihood of cure is low, but also thinking about how do we integrate these therapies early in the treatment landscape to enhance cure rates for patients, which is just really spectacular. We're seeing many of these agents move into the perioperative setting or in combination with radiation for localized disease. And then the special symposium on biomarkers, I mean, we've really come a long, long way. And I think that we're going to continue to evolve over the next several years. I'm super excited about where the field is going in the treatment of genitourinary malignancies. Dr. Pedro Barata: Oh, absolutely true. And I would say within the Annual Meeting, we have outstanding Educational Sessions. And just a reminder to the listeners that actually that's where the different teams or topics for the Educational Book chapters come from, from actually the educational sessions from ASCO. And your fantastic chapter is an example of that, right, focusing on advanced GU tumors. So, thank you so much, Rana, for taking the time, sharing your insights with us today on the podcast. It was a fantastic conversation as always. Dr. Rana McKay: My pleasure. Thanks so much for having me, Dr. Barata. Dr. Pedro Barata: Of course.  And thank you to our listeners for your time today. You will find the link to the article discussed today in the transcript of this episode. I also encourage you to check out the 2025 ASCO Educational Book. You'll find an incredible wealth of information there. It's free, available online, and you'll find, hopefully, super, super important information on the key science and issues that are shaping modern oncology, as we've heard from Dr. McKay and many other outstanding authors. So, thank you, everyone, and I hope to see you soon. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Pedro Barata @PBarataMD Dr. Rana McKay @DrRanaMcKay Follow ASCO on social media:        @ASCO on X (formerly Twitter)        ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Pedro Barata: Stock and Other Ownership Interests: Luminate Medical Honoraria: UroToday Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck  Dr. Rana McKay: Consulting or Advisory Role: Janssen, Novartis, Tempus, Pfizer, Astellas Medivation, Dendreon, Bayer, Sanofi, Vividion, Calithera, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seattle Genetics, Telix, Eli Lilly, Blue Earth Diagnostics, Ambrx, Sumitomo Pharma Oncology, Esiai, NeoMorph, Arcus Biosciences, Daiichi Sankyo, Exelixis, Bristol Myers Squibb, Merck, Astrazeneca, Myovant Research Funding (Inst.): Bayer, Tempus, AstraZeneca, Exelixis, Bristol Myers Squibb, Oncternal Therapeutics, Artera    

In this episode of the Mic On Podcast, Seun Okinbaloye sits with political commentator Henry Shield, who delivers a blistering take on Nigeria's opposition.Shield brands the PDP “a dead party,” predicts a split between Nyesom Wike's camp and its traditional bloc, and accuses its leaders of selling out to the APC. He singles out Bauchi Governor Bala Mohammed as “walking alone” in trying to revive the party.Looking to 2027, Shield warns that without unity between Jonathan, Atiku, and Obi, President Tinubu will win again. He called the ADC the only party with “a slim chance” and says the next election would be “a war of everything.”Guest:Mr Henry Shield(Leadership & Accountability Advocate, Political Commentator).

Editor-in-Chief of the Archives of Disease in Childhood, Dr. Nick Brown, and Senior Editor of ADC, Dr. Rachel Agbeko bring you the monthly Atoms - the highlights of the September 2025 issue. Read it on the Archives of Disease in Childhood website: https://adc.bmj.com/content/110/9/i       Please listen to our regular podcasts and subscribe in Apple Podcasts, Google Podcasts, Stitcher and Spotify to get episodes automatically downloaded to your phone and computer. And if you enjoy the podcast, please leave us a review at https://podcasts.apple.com/gb/podcast/adc-podcast/id333278832

Abel Mateus, antigo presidente da AdC, afirma estar "muito preocupado" com a aplicação da Lei da Concorrência em Portugal. E defende que anulação de coimas do "cartel da banca" gera impunidade.See omnystudio.com/listener for privacy information.

In Kaduna, suspected political thugs stormed an ADC meeting, leaving chaos and fear in their wake. Barely days later in Kebbi State, an ADC convoy was attacked on the road.Two violent incidents in just one week  targeting the same political party. And yet, the 2027 elections are still two years away.If this is how the political season is beginning, what should Nigerians expect as we draw closer to the polls? Could 2027 turn into one of Nigeria's most violent elections yet?In today's episode of Nigeria Daily, we take a closer look at these troubling events, speaking with victims, political actors, the police, and analysts on what this could mean for Nigeria's democracy.

We jet off to Central London to meet Robin Carr, CEO of Myricx Bio, a startup developing antibody-drug conjugates (ADCs) to treat cancer.The team's idea – using a novel ADC payload inhibiting molecules called N-myristoyltransferases (NMTs) – helped them to bag an impressive £90M ($114M) Series A round in 2024.Robin outlines Myricx's journey from small molecule antivirals to the booming market of cancer ADCs, and how the transition from big pharma to biotech has been an energising experience for him.--------------------This episode is sponsored by Kadans. Learn more about Kadans' London Innovation Centre where life sciences companies grow from start-up to global player: https://bit.ly/kadans-myricxbio--------------------⭐️ ABOUT THE SPEAKERRobin kicked off his Myricx experience as chief development officer in November 2019, before rising to the CEO seat in August 2022. Before this, he was VP of drug discovery at Astex Therapeutics, before spending more than a decade in research executive roles at GSK. ending up as SVP Drug Design and Selection.

ChatGPT hier, Co-Pilot daar. Elke organisatie wil wel ‘iets met AI'. Maar veel initiatieven verzanden in vrijblijvende probeersels. De IT-afdeling rommelt wat aan, de directie wacht af, en ondertussen blijft echte transformatie uit.Elianne Anemaat, AI specialist bij ADC, ziet het dagelijks gebeuren. Zij helpt organisaties bij het verantwoord én effectief invoeren van AI. Niet door er wat tools doorheen te drukken, maar door strategie en structuur aan te brengen. Zij stelt vragen als: Wat wil je bereiken? Wat past bij jouw organisatie? En: durf je als leider zélf het voortouw te nemen?In deze aflevering leer je:Waarom “We gebruiken Co-Pilot” net zo nietszeggend is als “We doen iets met internet”Hoe je van AI een hefboom maakt, in plaats van een speeltjeWaarom leiderschap essentieel is, ook als je geen techneut bent“Je wint of je leert. Het is pas falen als je niks doet met de uitkomst.”Ben jij ook klaar met die AI-proefballonnen en wil je écht stappen zetten in je organisatie? Luister DenkTank, de podcast van DenkProducties.Meer weten?- Meld jouw AI charity project aan zodra de inschrijving open gaat bij ADC (website en LinkedIn)- Kom naar Amsterdam Business Forum en bezoek de AI Deepdive van ADC. Inschrijven doe je op denkproducties.nl

Remixed- Path to KOLs: The New Chemist Podcast's Global Journey in Science, Pharma, and Education: Interview with Mohan Uttarwar, CEO & Co-Founder of 1Cell.Ai---In this episode we provide and educational episode remix made with software assistance ( for educational purposes only) , we sit down with Mohan Uttarwar, CEO & Co-Founder of 1Cell.Ai, to explore how AI-driven single-cell analytics are revolutionizing precision oncology. Discover how the OncoIncytes platform merges ctDNA, live CTCs, single-cell RNA and proteomics for a real-time, multimodal tumor profile—and learn how these insights are sharpening patient selection, accelerating ADC trials, and delivering earlier, more accurate measures of therapeutic response. Mohan also shares his playbook for building a capital-efficient biotech across Silicon Valley and India, the emerging trends set to reshape drug development, and practical advice for chemists, data scientists, and founders looking to break into the field. Tune in this August for a deep dive into the future of cancer research and drug discovery.--Please note: The views of this podcast represent those of my guest(s) and I, and do not constitute professional or medical advice or consultation. Please see a medical professional or healthcare professional for advice, suggestions and consultations. We disclaim any loss in any way.Music citation: Open source

In Nigerian politics, the idea of zoning has grown into an unwritten rule a delicate balancing act meant to ensure fairness in power-sharing across regions. For decades, it has shaped who gets to lead and from where. Already, the two dominant parties, PDP and APC, have thrown their weight behind the South for the 2027 presidential race. But the ADC is charting a different course, arguing that leadership should be anchored on competence and merit rather than geography.So, what does this mean for Nigeria's democracy, and how might it reshape the fierce contest ahead? In this episode of Nigeria Daily, we break down the politics of zoning, the stakes for 2027, and what it could mean for the future of leadership in Africa's largest democracy.

Can you give patients one ADC after another? A renowned panel of experts interrogate this question and many more in this thought-provoking program. Credit available for this activity expires: 8/25/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002851?ecd=bdc_podcast_libsyn_mscpedu

Are you looking to save time, make money, and start winning with less risk? Then head to https://www.ovtlyr.com.The stock market is sending some serious warning signs right now. If you've been trying to buy the dip, dollar cost averaging your way down, or chasing every bounce, you're probably feeling the pain. This video breaks down why sitting on the sidelines can sometimes be the smartest trade, how to recognize trend shifts before they smack you in the face, and where the real opportunities might show up next.We dive deep into the importance of having a rules-based plan, why consistency and discipline matter more than hype, and how the OVTLYR signals are pointing to some major shifts under the surface. From market breadth and fear vs. greed readings to sector breakdowns and individual stock setups, this is your chance to see exactly what's happening behind the curtain.One of the big takeaways here: you don't have to catch every move. Winners average winners, losers average losers. If the market is running hot with greed, that's often when a snapback is lurking around the corner. Understanding when to sit out and when to strike is what separates disciplined traders from gamblers.Inside this session, we cover:➡️ Why dollar cost averaging in a downtrend can turn into a costly mistake➡️ The power of “sit out” trades and why cash is sometimes the best position➡️ Key lessons from OVTLYR's nine-signal system and how fewer signals can actually lead to more trades➡️ What market breadth, sector rotations, and fear/greed indicators are flashing right now➡️ Stock-specific breakdowns, including Nvidia ahead of earnings, sector leaders, and a few surprising setups in utilities, staples, and communicationsYou'll also see how order blocks reveal where buyers keep getting trapped, why some charts scream “strong buy” while others are flashing “GTFO,” and how expected moves in the options chain can set realistic expectations for volatility. Whether it's Nvidia, Palantir, Duke Energy, or lesser-known tickers like ADC, BZ, and GFL, the same rules apply: risk comes first, profits follow.This isn't about gambling on earnings or hoping for miracle rebounds. It's about protecting your capital, waiting for high-probability setups, and trading with confidence when the odds are finally stacked in your favor. If you've ever been burned holding through a big report, or found yourself stuck in a sideways chop, this breakdown is going to help you see the market differently.Remember, the market doesn't care about opinions—it only cares about price, trend, and momentum. Learn how to read those signals, avoid common traps, and put yourself in a position to win more and risk less.If you're serious about trading smarter, stick around until the end. There's money to be made, but only if you follow your plan, stay disciplined, and keep risk management front and center.Gain instant access to the AI-powered tools and behavioral insights top traders use to spot big moves before the crowd. Start trading smarter today

Antibody-drug conjugates (ADCs) are a relatively new type of medicine for breast cancer. Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) and Dato-DXd (brand name: Datroway) are two ADCs used to treat breast cancer. Dr Benjamin Schrank and colleagues have developed a new type of ADC that combines an antibody with a toxin — called an antibody-toxin conjugate — that teaches the immune system to recognize and attack cancer cells. Listen to the episode to hear Dr. Schrank explain: the antibody and the toxin component of the medicine how the new medicine works possible side effects next steps for the research Episode image photo credit: The University of Texas MD Anderson Cancer Center

La chorégraphe et danseuse suisse Yasmine Hugonnet présente 1000&1 BPM à voir du 28 août au 2 septembre au Pavillon de lʹADC dans le cadre du Festival de la Bâtie. A noter que dès lundi prochain, lʹémission La vie à peu près sur RTS Espace 2, déroule le portrait de Yasmine Hugonnet en 5 épisodes, de 13.30 à 14.00. Elle est au micro dʹAnya Léveillé.

In this podcast "Treatment Optimization and Management of AEs with Enfortumab Vedotin + Pembrolizumab for Untreated Locally Advanced/Metastatic Urothelial Cancer: A Podcast", authors discuss the management of adverse events (AEs) with enfortumab vedotin + pembrolizumab based on their personal experiences with clinical trials and in their practices and provide perspectives for healthcare professionals on practical management of common AEs and effective dose management strategies. This may help improve the patient experience and allow patients to stay on therapy for longer, leading to optimized treatment outcomes. This podcast is published open access in Oncology and Therapy and is fully citeable. You can access the original published podcast article through the Oncology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40487-025-00369-9. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

三商行控股集團從食品、零售到健康產業，一直專注陪伴著台灣人的生活。如今這份用心也延伸到了高專業、高風險的生物科技領域，由嘉正生物科技扮演關鍵角色。今天的來賓，是嘉正生物科技副董事長暨副總經理，也是三商行控股集團的重要推手──林瑟宜女士。她帶著25年的跨國藥廠豐富經歷，回到台灣，引領嘉正在研發、國際布局與企業永續之路上穩健前行。今年更帶領團隊拿下2025亞太生物製藥卓越獎，成為台灣第一ADC研發團隊。生技產業需要高技術研發與高投資，因此在台灣一直有許多障礙有待克服。林副董如何引進國外大藥廠的管理經驗，結合三商行的人本關懷企業文化？她自身的女性特質對管理上有何助益？一起來聽她精彩的分享。

This week on Dividend Talk, Derek is joined by Jeremy from Dividend Stockpile to explore some of the biggest Megatrends shaping our investing future. We cover the opportunities and risks in infrastructure, clean energy, technology, and healthcare, and how dividend investors can position themselves for the next decade and beyond.You'll hear about recent dividend news from Interface (TILE) and Agree Realty (ADC), how US and European infrastructure approaches differ, why utilities like Iberdrola (IBE.MC) and Enel (ENEL.MI) stand out, and how tech giants Meta (META), Alphabet (GOOG), and Microsoft (MSFT) fit into the AI megatrend. We also look into healthcare innovation, options income strategies, and favourite finance content creators.Tickers Mentioned: TILE, ADC, O, BAM, BIP, NEE, DUK, ED, IBE.MC, ENEL.MI, ABB, DG.PA, META, GOOG, MSFT, GE, CWEN, ASML.AS, SAP, MDT, MRK, ABBV, NVO, LLY, ROG.SW, SNY, SYK, ABT, BDX, RMD, STRCChapters:00:00 – Introduction & Guest Welcome02:52 – Company News: Interface & Dividend Increases05:41 – Agree Realty & REIT Quality08:43 – Understanding Megatrends11:51 – Infrastructure as a Megatrend29:06 – Clean Energy Transition39:31 – The Rise of Technology & AI46:51 – Healthcare Opportunities01:04:06 – Options Income Strategies & High Yield Ideas01:20:06 – Favorite Finance Content Creators & Closing RemarksGet a free sample of our premium dividend newsletter! Stay ahead of the market with in-depth stock analysis here: https://dividendtalk.eu/download-your-free-samples/ Stay Updated:Twitter - @DividendTalk_Twitter - @European_DGIJoin our Facebook Community - Dividend Talk Facebook GroupJoin our Discord group - https://discord.gg/nJyt9KWAB5

This week on EYE ON NPI we're featuring some open source hardware from one of our favorite hardware manufacturers! It's the Arduino Nano R4 System on Module (https://www.digikey.com/en/product-highlight/a/arduino/nano-r4) a miniaturized version of the Arduino UNO R4 and Minima (https://blog.adafruit.com/2023/07/27/eye-on-npi-arduino-uno-r4-minima-and-uno-r4-wifi-boards-digikey-arduino-digikey-adafruit/) versions we covered on EYE ON NPI about two years ago! taking a cue from popular 'castellated single side' PCB proto boards on the market, the Nano comes in two options, one with headers (https://www.digikey.com/en/products/detail/arduino/ABX00143/26766495) for easy installation into existing Arduino Nano expansion kits or breadboards, and one with reflowable castellations (https://www.digikey.com/en/products/detail/arduino/ABX00142/26766490) The Arduino Nano (https://www.digikey.com/en/products/detail/arduino/A000005/2638989) is second only to the UNO as the definitive Arduino board that 'everyone got started with'. Many folks would start with the chunky UNO and then migrate to the Nano to get something that plugs into a breadboard for compact assembly. With a USB connector on one end, button and LEDs and programming header on the top, this board powered tens of thousands of builds. So it's not surprising that Arduino iterated on this design with a wide variety of chips like the RP2040 (https://www.digikey.com/en/products/detail/arduino/ABX00052/14123941) and ESP32 (https://www.digikey.com/en/products/detail/arduino/ABX00092/21219771) The latest generation is the Renesas RA4M1 series - which updates the original ATmega328 8-bit microcontroller to a beefy Cortex M4 with FPU. You get 48MHz clock, 256KB of Flash, 32KB of SRAM, ADC, DAC, CAN, captouch and other extras. The FPU in particular makes it a nice upgrade to the cortex M0/M0+. The best part is that with the 5V logic support of the R7FA4M1AB3CFM (https://www.digikey.com/en/products/detail/renesas-electronics-corporation/R7FA4M1AB3CFM-AA0/10447195), it makes for a great drop-in replacement when a 3V logic chip like the RP2040/ESP32 won't work as well. Plus you get lots of nice linear ADCs, the RP2040 only has 4 and the ESP32's are non-linear and sometimes don't work when WiFi is active. We also love that they added a Qwiic (https://www.sparkfun.com/qwiic) connector on the end! We use this for all our Stemma QT sensors, and between the many companies that have joined in the ecosystem there are easily a thousand different ons/displays/accessories that can plug in directly for instant expansion. If you want to get the latest Nano from the manufacturer of genuine Arduino boards, DigiKey is a authentic distributor and has tons of the Arduino Nano R4 (https://www.digikey.com/short/3brjrnjp) in stock right now for (https://www.digikey.com/en/products/detail/arduino/ASX00061/26744081) immediate shipment! Pick from the castellated flat or soldered-header variety, and don't forget to also grab some Arduino Nano accessories to get your design prototyped fast. Order today and your Nano will fly out of the DigiKey warehouse and arrive at your doorstep by tomorrow morning.

In a dramatic turn of events, the Economic and Financial Crimes Commission (EFCC) has been summoning some of Nigeria's most prominent politicians for questioning over the past six months. But as the list of invitees grows, so do allegations of political bias. Critics claim that many of those being probed belong to opposition parties, fueling speculation that the EFCC is being wielded as a tool for political vendetta. In today's episode of Nigeria Daily, we'll take a closer look at the politicians who've been called in, and explore the burning question: are these investigations genuinely about holding public officials accountable, or are they just a manifestation of politics as usual?

In this episode of the Mic On Podcast, Seun Okinbaloye sits with the Hon. Leke Abejide, who defends his influence in the African Democratic Congress (ADC) while dismissing his suspension as politically motivated.Abejide recounts introducing the ADC to his constituency, declares himself “the landlord of the ADC,” and predicts President Bola Tinubu will win 32 out of 36 states in 2027. He dismisses Goodluck Jonathan and Peter Obi as serious threats, praises Tinubu's economic reforms, and accuses opposition figures of destabilizing his party.Guest:Hon. Leke Abejide(Federal Lawmaker, Yagba Federal Constituency, Kogi State)

Joel Campe ist davon überzeugt: gesellschaftlicher Wandel ist nötig – und möglich! Joel Campe unterstützt Organisationen, Projekte und Initiativen darin, handlungsfähig zu werden und zu bleiben und sich wirksam für Veränderungen hin zu einer solidarischen, zukunftsfähigen Welt zu engagieren. Geleitet von dem Wunsch, nicht nur über Wandel zu reden sondern ihn aktiv in die Welt zu tragen ist Joel nach einem Ökolandbau-Studium im Jahr 2003 ins Ökodorf Sieben Linden gezogen. Joel hat hier Permakultur z.B. in einem Waldgarten, in der Siedlungsgestaltung und in Organisationsentwicklungsprozessen angewandt. In der langjährigen Mitarbeit an der Permakultur Akademie hat Joel gemeinsam mit Kolleg*innen mit Permakultur Design erfolgreiche Bildungsprogramme entwickelt. Joel bietet Supervision, Moderation und Prozessbegleitung sowie Coaching, Konfliktmoderation und Trainings an, geleitet von Werten wie Globaler Gerechtigkeit, Solidarität und echter Nachhaltigkeit. Gloria Kison ist eine preisgekrönte Designerin, die lieber aussteigt, als sich verbiegt und heute Stressresilienz unterrichtet. Sie hat eine Laufbahn eingeschlagen, die man nicht plant, sondern spürt. Schon im Kommunikationsdesign-Studium an der Hochschule RheinMain wurde ihr klar, dass sich in der Branche vieles eher um Ego als um Eco dreht. Bei Scholz & Volkmer, wo sie bereits als Studentin arbeitete, entwickelte sie 2014 ihre Bachelorarbeit: das Kiezkaufhaus – ein Online-Marktplatz für lokale Händler mit nachhaltiger Same-Day-Lieferung per E-Bike. Das vielfach ausgezeichnete Projekt (u.a. Red Dot Design Award, ADC, DDC, UX Design Award, Deutscher Digital Award) hätte ihr den Weg in große Agenturen geöffnet. Doch Gloria entschied sich 2015 bewusst für einen anderen Kurs: selbstständig, unabhängig, mit Fokus auf nachhaltige, sinnstiftende Gestaltung. Ihr Designansatz basiert auf den Prinzipien der Permakultur – ressourcenschonend, systemisch und nutzerfreundlich. Dieser Wandel führte sie nicht nur beruflich, sondern auch persönlich in eine neue Richtung – ins Ökodorf Sieben Linden, wo sie heute lebt, gestaltet und eine enkeltaugliche Zukunft mitformt. Thomas Jäger ist Vorstand des DDC, Permakultur-Enthusiast und Humanitarian Designer mit einem besonderen Fokus auf systemisches Denken und soziale Transformation. In seiner internationalen Arbeit verbindet er seit Jahren Gestaltung mit sozialen und ökologischen Herausforderungen – insbesondere dort, wo komplexe Krisen nachhaltige und kontextbasierte Antworten erfordern. Neben seiner Arbeit in humanitären und sozialunternehmerischen Kontexten – etwa im Libanon, in Griechenland, Peru und Äquatorialguinea – reichen seine Berührungspunkte mit Permakultur von Community-Gärten in Geflüchtetenprojekten über Beratungsprojekte auf landwirtschaftlichen Flächen in Marokko bis hin zur Entwicklung eines Sensorsystems und Erntewerkzeugs im Rahmen eines Kakao-Projekts mit Kleinbauern in Westafrika. Permakulturprinzipien spielten dabei eine tragende Rolle – nicht nur landschaftlich, sondern auch als methodischer Rahmen in der sozialen Gestaltung. Michael Menge, 1985 in Duisburg geboren, ist Master of Arts. 2008-2013 studierte er an den Hochschulen Köln und Mainz. Umfassende internationale Berufserfahrung in verschiedenen Sparten der visuellen Kommunikation sammelte er bei verschiedenen Design Unternehmen in Festanstellung und Freelancer Lange und Durach, Köln; Digital Eskimo, Sydney; Baggen Design, Düsseldorf; Saatchi&Saatchi, Düsseldorf; Ogilvy, Düsseldorf; GSVI, Bochum Mit seinem Design Büro studio franz, was er 2022 gegründet hat arbeitet er europaweit für Kunden vom internationalen Mittelstand bis zu Museen in Wien. Die Arbeiten, die in den letzten Jahren entstanden sind, wurden mit zahlreichen branchenrelevanten Preisen geehrt, darunter: 5* red dot, 1* red dot best of the best 1*The finest agencies germany, 5* Corporate Design Preis, 2* IF Design Award, 4* German Design Award Special Mention, 3* German Brand Award nominee, 1* Shortlist

Cet épisode est présenté par Squarespace.La plateforme tout-en-un pour créer un site élégant et professionnel, même sans compétences techniques.Templates au design impeccable, outils puissants, et un assistant IA qui simplifie tout.Essayez gratuitement 14 jours et profitez de -10 % avec le code BOLD sur squarespace.com/BOLD.

The Making of KOLs: The New Chemist Podcast's Global Journey in Science, Pharma, and Education: Interview with Mohan Uttarwar, CEO & Co-Founder of 1Cell.Ai---In this episode , we sit down with Mohan Uttarwar, CEO & Co-Founder of 1Cell.Ai, to explore how AI-driven single-cell analytics are revolutionizing precision oncology. Discover how the OncoIncytes platform merges ctDNA, live CTCs, single-cell RNA and proteomics for a real-time, multimodal tumor profile—and learn how these insights are sharpening patient selection, accelerating ADC trials, and delivering earlier, more accurate measures of therapeutic response. Mohan also shares his playbook for building a capital-efficient biotech across Silicon Valley and India, the emerging trends set to reshape drug development, and practical advice for chemists, data scientists, and founders looking to break into the field. Tune in this August for a deep dive into the future of cancer research and drug discovery.--Please note: The views of this podcast represent those of my guest(s) and I.Music citation: Open source

“Colorectal cancer treatment is not just about eliminating a disease. It's about preserving life quality and empowering patients through every phase. So I think nurses are really at the forefront that we can do that in the oncology nursing space. So from early detection to survivorship, the journey is deeply personal. Precision medicine, compassionate care, and informed decision-making are reshaping outcomes. Treatment's just not about protocols. It's about people,” ONS member Kris Mathey, DNP, APRN-CNP, AOCNP®, gastrointestinal medical oncology nurse practitioner at The James Cancer Hospital of The Ohio State University Wexner Medical Center in Columbus, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about colorectal cancer treatment.  Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 1.0 contact hour of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by August 1, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase in knowledge related to the treatment of colorectal cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 370: Colorectal Cancer Screening, Early Detection, and Disparities Episode 153: Metastatic Colorectal Cancer Has More Treatment Options Than Ever Before ONS Voice articles: Colorectal Cancer Prevention, Screening, Treatment, and Survivorship Recommendations Genetic Disorder Reference Sheet: Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) How Liquid Biopsies Are Used in Cancer Treatment Selection Oncology Drug Reference Sheet: 5-Fluorouracil Oncology Drug Reference Sheet: Oxaliplatin What Is a Liquid Biopsy? Clinical Journal of Oncology Nursing article: Colorectal Cancer in Young Adults: Considerations for Oncology Nurses Oncology Nursing Forum article: Neurotoxic Side Effects Early in the Oxaliplatin Treatment Period in Patients With Colorectal Cancer ONS Colorectal Cancer Learning Library ONS Biomarker Database (filtered by colorectal cancer) ONS Peripheral Neuropathy Symptom Interventions American Cancer Society colorectal cancer resources CancerCare Colorectal Cancer Alliance Colorectal Cancer Resource and Action Network Fight Colorectal Cancer National Comprehensive Cancer Network To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Colorectal cancer has several different types, but there is one that dominates the landscape, and that is adenocarcinoma. So I think most of us have heard that. It's fairly common, and it accounts for about 95% of all colorectal cancers. It begins in the glandular cells lining the colon or rectum and often develops from polyps, in particular adenomatous polyps.” TS 1:41 “One of the biomarkers that we'll most commonly hear about is KRAS or NRAS mutations. This indicates tumor genetics, and these mutations suggest resistance to our EGFR inhibitors such as cetuximab. BRAF mutation or V600E is a more aggressive tumor subtype, and those may respond to our BRAF targeted therapy. … And then our MSI-high or MMR-deficient—microsatellite instability or mismatch repair deficiency—that really predicts an immunotherapy response and may indicate Lynch syndrome, which is a huge genetic component that takes a whole other level of counseling and genetic testing with our patients as well.” TS 6:02 “Polypectomy or a local excision—that removes our small tumors or polyps during that colonoscopy. And that's what's used for those stage 0 or early stage I cancers. A colectomy removes part or all of the colon. This may be open or laparoscopic. It can include a hemicolectomy, a segmental resection, or a total colectomy, so where you take out the entire part of the colon. A proctectomy removes part or all of the rectum. This may include a low anterior resection, also known as an LAR … or an abdominal perineal resection, which is an APR. … Colostomy or ileostomy—that diverts the stool to an external bag via stoma. Sometimes this is temporary or permanent depending on the type of surgery.” TS 14:11 “We'll have our patients say, ‘Hey, I want immunotherapy therapy. I see commercials on it that it works so well.' We have to make sure that these patients are good candidates for it, also that we're treating them adequately. We need to make sure that they have those biomarkers, so as I mentioned, the MSI-high or MMR tumors. Our MSS-stable tumors—they may benefit from newer combinations or clinical trials. Metastatic disease—immunotherapy may be used alone or with other treatments. And then in the neoadjuvant setting, some trials are really showing promising results using immunotherapy prior to surgery.” TS 25:38 “Antibody-drug conjugates are really an exciting frontier in all cancer treatments as well as colorectal cancer treatment. This is used mainly for patients with advanced or treatment-resistant disease, and these therapies combine the targeted power of monoclonal antibodies with the cell-killing ability of potent chemotherapy agents. They're still on the horizon for the most part in colorectal cancer. However, there is only one approved antibody-drug conjugate, or ADC, at this time, and that's trastuzumab deruxtecan, or Enhertu. That's approved for any solid tumor, such as colorectal cancer with HER2 IHC 3+. So again, looking back at that pathology in those markers, making sure that you have that HER2 mutation and that IHC.” TS 35:00 “There are a few myths going around about colorectal cancer treatment that can lead to confusion or even delayed care. One myth is only older men get colorectal cancer. As you heard me talk in my previous podcast on screening, unfortunately, this isn't necessarily true. Colorectal cancer affects both men and women and our cases in the younger population are rising. So our screening guidelines have changed to age 45 because we are seeing it in the younger population.” TS 45:54

In this special episode of Dividend Talk, we tackle one of the most frustrating topics for European investors: dividend withholding tax. Our guest is Thomas Rappold, founder of Divizend.com, a platform built to automate and simplify dividend tax reclaims for retail investors. Thomas shares how his own investing struggles led him to build the company, and how Divizend is helping thousands of investors recover lost income from foreign dividends.We discuss:​What dividend withholding tax is (and why it's such a headache)​Why most investors miss out on reclaiming what's rightfully theirs​The upcoming EU-Faster regulation and digital tax residency certificates​The role of brokers, the EU Commission, and what's changing by 2028​Practical steps for reclaiming your foreign dividend taxes​Why dividend investors need to push for change and how Divizend is giving us a voice​Thomas also shares his unique investing mindset (yes, he owns both Palantir and Lindt!) and replaces a stock in our Dividend Growth Community Portfolio.

Welcome back to The Dive Driven by Kia! Kobe, Azael and Meteos look ahead to 4 more years of T1 Faker before breaking down 4 opening week sweeps in the LTA North. After the break, we look ahead to this weekend's matchups as chosen by the teams themselves. Finally, Patch 25.15 is live! The crew discusses Braum nerfs, the state of ADC and more.Timestamps:0:00 - Intro & Faker Re-signs to T18:15 - Travis Gafford Steps Away12:37 - LTA Split 3 Format17:13 - Team Liquid vs 100 Thieves Review34:23 - Shopify Rebellion vs Dignitas Review45:21 - Cloud9 vs Lyon Review53:51 - FlyQuest vs Disguised Review1:01:56 - Week 2 Matches Preview1:11:18 - Patch 25.151:19:48 - ADC & Balance Debate 

In this episode, listen to Laura M. Spring, MD; and Shipra Gandhi, MD, MS, share their takeaways from a large educational program on available and emerging first-line treatment options for patients with HER2-positive mBC:Emerging new data from the phase IIII DESTINY-Breast09 trial of first-line treatment with trastuzumab deruxtecan ± pertuzumab vs THP for advanced HER2-positive breast cancerInteractive decision support tool with recommendations from 5 experts for the treatment of HER2-positive breast cancerOutcomes data from a live webinar on applying the latest data for first-line management of HER2-positive mBC, including analyzing the latest clinical results and developing tailored interventions to address challenges with novel ADCs Program faculty:Laura M. Spring, MDBreast Medical OncologistMass General Hospital Cancer CenterHarvard Medical SchoolBoston, Massachusetts Shipra Gandhi, MD, MSAssociate ProfessorDirector, Breast Translational ResearchGlenn Family Breast CenterWinship Cancer Institute of Emory UniversityAtlanta, GeorgiaResources:To access the interactive patient cases associated with this podcast discussion, please visit the program page, to access a recording from a live webinar, and an interactive decision support tool on this topic.

Welcome back to another episode of The Dive Driven by Kia. Champion designer Riot Yelough joins Kobe and Meteos to give some behind-the-scenes intel on the new ADC champ Yunara. Kobe pitches us on his Yunara build (Hullbreaker, Hexplate, Hurricane) and we go over expectations for Yunara in pro play. Will we see Yunara on the LTA stage this weekend? Plus, we break down Patch 25.14, 100 Thieves' last dance, LTA North roster changes and power rankings for Split 3.Finally, make sure to grab tickets for LTA Split 3! Tickets are still available for Opening Week and throughout the entire split, including the LTA Championship in Texas. This Saturday at the Riot Games Arena in LA enjoy a Spirit Blossom themed Opening Day tailgate after the games where you can get a free Spirit Blossom Teemo skin, win prizes, buy some merch (including the exclusive LTA Poro), meet the teams, enjoy free food and more!Purchase your tickets for LTA's Split 3 here: https://www.tixr.com/groups/ltanorth/events/2025-lta-north-split-3-mastercard-opening-week-day-1-150643And get your tickets to the LTA Championship here: https://www.ticketmaster.com/league-of-legends-tickets/artist/2144001Timestamps:0:00 - Introduction with Yunara's Designer Riot Yelough4:54 - Initial Reactions with Yunara's Launch13:23 - Yunara's Itemization22:57 - Thoughts on Yunara in Pro Play33:38 - Evolution of Skill Expression37:57 - Favorite Moments from MSI41:50 - Fantasy is Back42:58 - Patch 25.1455:23 - 100T's Exit from the LTA1:04:53 - LTA Roster Changes1:21:29 - Power Rankings

In this episode, CancerNetwork® spoke with breast oncologists Heather McArthur, MD; Erika Hamilton, MD; Hope Rugo, MD; and Paolo Tarantino, MD, PhD, about advances in breast cancer. These developments included recent drug approvals and ongoing research for therapeutic approaches, particularly in the areas of antibody-drug conjugates (ADCs) and CDK4/6 inhibitors, based on presentations they gave at the 25th Annual International Congress on the Future of Breast Cancer (IBC) East in New York City. Initially, McArthur, Komen Distinguished Chair in Clinical Breast Cancer Research at the Harold C. Simmons Comprehensive Cancer Center, discussed immunotherapy use in high-risk triple-negative and HER2-positive disease, the evolving role of adjuvant CDK4/6 inhibition in HER2-negative breast cancer, and potentially transformative advancements in early breast cancer treatment.  She highlighted the FDA approval for pembrolizumab (Keytruda) in early-stage triple-negative breast cancer, promising clinical trials in estrogen receptor (ER)–positive high-risk early-stage breast cancer, and data from an investigator-initiated trial to treat HER2-positive disease. Additionally, she highlighted an 8.5% improvement in pathological complete response with pembrolizumab added to immunotherapy in the phase 3 KEYNOTE-756 trial (NCT03725059), adding that a further event-free survival benefit may complicate the landscape for CDK4/6 inhibition based on lung and liver toxicities associated with the coadministration of these inhibitors with immunotherapy.1 McArthur expressed further excitement for ADC-based combinations for triple-negative disease, as well as in the high-risk residual disease setting. In addition, she highlighted potential advancements in de-escalation strategies and further considerations for ADCs in the HER2-positive and hormone receptor (HR)–positive spaces. Then, Hamilton, director of Breast Cancer and Gynecologic Cancer Research at the Sarah Cannon Research Institute, highlighted emerging therapies for early breast cancer, as well as her use of datopotamab deruxtecan-dlnk (dato-DXd; Datroway) and fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) given their recent approvals in various breast cancer subtypes. She also touched upon challenges with respect to the implementation of new therapies for early breast cancer into clinical practice. She initially highlighted new data from the phase 3 VERITAC-2 trial (NCT05654623) presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.2 Specifically, findings showed that vepdegestrant, an oral proteolysis-targeting chimera (PROTAC), exhibited an efficacy advantage over fulvestrant (Faslodex) in patients with ESR1-mutant ER-positive, HER2-negative advanced or metastatic disease. Moreover, she highlighted data from the phase 3 DESTINY-Breast09 (NCT04784715) of T-DXd in various combinations for patients with HER2-positive metastatic breast cancer.3 Hamilton further highlighted her implementation of T-DXd into clinical practice, citing her use of the agent in patients with metastatic disease, including those with HER2-low and HER2-ultralow breast cancer. She further differentiated dato-DXd from T-DXd, suggesting that they were different classes of drugs due to their different targets: TROP2 vs HER2. She concluded by highlighting an unmet need regarding sustained benefit from endocrine therapy in HR-positive disease, as well as for ADC sequencing and mechanisms of resistance. Afterward, Rugo, division chief of Breast Medical Oncology, Women's Cancer Program Director, and professor in the Department of Medical Oncology and Therapeutics Research at City of Hope, discussed efficacy and safety considerations for CDK4/6 inhibitors in early breast cancer treatment. Specifically, she highlighted their high tolerability despite adverse effects and costs associated with their use. Rugo further touched upon a reduction of recurrence rates associated with CDK4/6 inhibition, although longer-term follow-up data were warranted to optimize the duration of therapy and elucidate survival outcomes. Finally, Tarantino, a research fellow at the Dana-Farber Institute, concluded by discussing sequencing strategies for ADCs, as well as which breast cancer settings or patient populations will experience the greatest impact with this treatment modality. Tarantino discussed his use of the “sandwich strategy,” where he switches the mechanism of action of treatment after using a TOPO1 ADC. Furthermore, Tarantino highlighted data from the DESTINY-Breast09 and phase 3 ASCENT-04 (NCT06100874) trials, which displayed the enhanced efficacy of 2 ADC combination therapies.4 He concluded by discussing future considerations for combining multiple ADCs. References 1. Cardoso F, O'Shaughnessy J, Liu Z, et al. Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial. Nat Med. 2025;31(2):442-448. doi:10.1038/s41591-024-03415-7 2. Hamilton E, De Laurentiis M, Jhaveri K, et al. Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: results of the global, randomized, phase 3 VERITAC-2 study. J Clin Oncol. 2025;43(suppl 17):LBA1000. doi:10.1200/JCO.2025.43.17_suppl.LBA1000 3. Tolaney S, Jiang Z, Zhang Q, et al. Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): interim results from DESTINY-Breast09. J Clin Oncol. 2025;43(suppl 17):LBA1008. 4. Tolaney SM, de Azambuja E, Kalinsky K, et al. Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study. J Clin Oncol. 2025;43(suppl 17):LBA109. doi:10.1200/JCO.2025.43.17_suppl.LBA109

The People's Democratic Party (PDP) has been making headlines, not for electoral victories, but for quietly tolerating internal betrayal. Despite members openly supporting rival parties like APC, LP, SDP, and now ADC, the party has taken little or no disciplinary action. In this episode of Nigeria Daily, we ask: is this strategic silence, political weakness, or a total collapse of party discipline?

CME credits: 0.50 Valid until: 17-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/contrasting-trop2-targeted-adcs-in-breast-cancer-therapy/33024/ This online chapterized CME activity features Drs. Kevin Kalinsky and Komal Jhaveri in a discussion on TROP2-targeted antibody-drug conjugates (ADCs) for metastatic breast cancer (mBC). The faculty describe the therapeutic role of TROP2 as well as both approved and investigational ADCs that target TROP2. Clinical trial data on TROP2-targeted ADCs from various studies are reviewed to evaluate their efficacy and safety across hormone receptor–positive and triple-negative disease settings. The discussion contrasts molecular structures, dosing schedules, and toxicity profiles of each ADC, providing insight into their positioning in treatment algorithms. Practical strategies for therapy sequencing, patient selection, and shared decision-making are emphasized throughout.=

This week's EYE ON NPI is

The boys discuss the ADC role, League Trivia, MSI, and more on episode 698 of Leaguecast! Email us - mail@leaguecastpodcast.com   Support us - https://www.patreon.com/leaguecast  Tweet us - https://twitter.com/leaguecast   Facebook - https://www.facebook.com/Leaguecast/   Join Our Discord - https://discord.gg/leaguecast  Visit our Website - https://leaguecastpodcast.com/

Drs. Yuan and Callahan discuss data presented at ASCO 2025 about DESTINY-Breast06, SHR-A1811, and TQB2101, along with real-world data on rechallenging patients with T-DXd post grade 1 ILD.

Editor-in-Chief of the Archives of Disease in Childhood, Dr. Nick Brown, and Senior Editor of ADC, Dr. Rachel Agbeko bring you the monthly Atoms - the highlights of the July 2025 issue. Read it on the Archives of Disease in Childhood website: https://adc.bmj.com/content/110/7/i      Please listen to our regular podcasts and subscribe in Apple Podcasts, Google Podcasts, Stitcher and Spotify to get episodes automatically downloaded to your phone and computer. And if you enjoy the podcast, please leave us a review at https://podcasts.apple.com/gb/podcast/adc-podcast/id333278832

NetScaler ADC and NetScaler Gateway Security Bulletin for CVE-2025-6543 Citrix patched a memory overflow vulnerability leading to unintended control flow and denial of service. https://support.citrix.com/support-home/kbsearch/article?articleNumber=CTX694788 Remote code execution in CentOS Web Panel - CVE-2025-48703 An arbitrary file upload vulnerability in the user (not admin) part of Web Panel can be used to execute arbitrary code https://fenrisk.com/rce-centos-webpanel Gogs Arbitrary File Deletion Vulnerability Due to the insufficient patch for the CVE-2024-39931, it's still possible to delete files under the .git directory and achieve remote command execution. https://github.com/gogs/gogs/security/advisories/GHSA-wj44-9vcg-wjq7 Let s Encrypt Will Soon Issue IP Address-Based Certs Let s Encrypt is almost ready to issue certificates for IP address SANs from Let's Encrypt's production environment. They'll only be available under the short-lived profile (which has a 6-day validity period), and that profile will remain allowlist-only for a while. https://community.letsencrypt.org/t/getting-ready-to-issue-ip-address-certificates/238777

Antibody drug conjugates, or ADCs, are still holding on to their spot as one of the hottest areas in cancer care—and AbbVie, like many of its peers, has embraced the trend head-on. In this week’s episode of "The Top Line," Fierce Pharma’s Zoey Becker speaks with Daejin Abidoye, M.D., AbbVie’s vice president and therapeutic area head for solid tumor oncology. They discuss the company’s evolution, trends from this year’s American Society of Clinical Oncology meeting and what’s ahead for ADCs in oncology. AbbVie, a newer player in the ADC space, recently earned FDA approval for Emrelis in adults with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have previously received systemic therapy. With a robust pipeline of ADCs in development, Abidoye envisions a bright future for the class—one that could herald “a new era” of cancer treatment beyond traditional chemotherapy. To learn more about the topics in this episode: AbbVie advances solid tumor agenda with FDA nod for lung cancer ADC Emrelis AbbVie pays $10B to acquire ImmunoGen, doubling down on red-hot ADC cancer field Replacing chemotherapy with ADCs? AbbVie rebuilds next-gen assets after Rova-T flop See omnystudio.com/listener for privacy information.

This week at the desk, we worked on getting more small hardware boards done. We revised our 1.5" transparent OLED breakout (oops, pins were swapped), designed breakouts for sensors like the AS5600 (https://www.digikey.com/en/products/detail/ams-osram-usa-inc/AS5600-ASOM/8250257) and STHS34PF80 (https://www.digikey.com/en/products/detail/stmicroelectronics/STHS34PF80/13187390), and updated the NAU7802 (https://www.digikey.com/en/products/detail/nuvoton-technology-corporation-of-america/NAU7802SGI/4929384) to have both ADC ports available. We're also working on another stepper motor driver, since the TMC2209 breakout (https://www.adafruit.com/product/6121) was a big hit. We wrapped and sent out the Triple-output Active Shifting RGB Matrix Bonnet (https://blog.adafruit.com/2025/02/28/triple-matrix-bonnet-makes-big-bright-displays/). Then we finally had a little time to get back into bigger projects, like Fruit Jam, which we re-picked-up! This week we focused on implementing the ESP32-C6 Wi-Fi co-processor, which needed a bit of rework, but now we've got rev C prototype PCBs on the way. ----------------------------------------- Visit the Adafruit shop online - http://www.adafruit.com LIVE CHAT IS HERE! http://adafru.it/discord Subscribe to Adafruit on YouTube: http://adafru.it/subscribe New tutorials on the Adafruit Learning System: http://learn.adafruit.com/ -----------------------------------------

This week at the desk, we worked on getting more small hardware boards done. We revised our 1.5" transparent OLED breakout (oops, pins were swapped), designed breakouts for sensors like the AS5600 (https://www.digikey.com/en/products/detail/ams-osram-usa-inc/AS5600-ASOM/8250257) and STHS34PF80 (https://www.digikey.com/en/products/detail/stmicroelectronics/STHS34PF80/13187390), and updated the NAU7802 (https://www.digikey.com/en/products/detail/nuvoton-technology-corporation-of-america/NAU7802SGI/4929384) to have both ADC ports available. We're also working on another stepper motor driver, since the TMC2209 breakout (https://www.adafruit.com/product/6121) was a big hit. We wrapped and sent out the Triple-output Active Shifting RGB Matrix Bonnet (https://blog.adafruit.com/2025/02/28/triple-matrix-bonnet-makes-big-bright-displays/). Then we finally had a little time to get back into bigger projects, like Fruit Jam, which we re-picked-up! This week we focused on implementing the ESP32-C6 Wi-Fi co-processor, which needed a bit of rework, but now we've got rev C prototype PCBs on the way. ----------------------------------------- Visit the Adafruit shop online - http://www.adafruit.com LIVE CHAT IS HERE! http://adafru.it/discord Subscribe to Adafruit on YouTube: http://adafru.it/subscribe New tutorials on the Adafruit Learning System: http://learn.adafruit.com/ -----------------------------------------

Exploring the emerging field of grief therapy with Dr. Tom Nehmy, a clinical psychologist specializing in Induced After Death Communication (IADC). We dive into how IADC uses EMDR techniques to help clients process sadness and facilitate after death communications, offering new pathways for healing. Tom shares his personal journey, the clinical research supporting IADC, and what differentiates genuine after death communications from imagination. We also touch on the role of intuition in therapy, the impact of spiritual experiences on grief recovery, and the growing need for spiritually-informed clinical practices. Head to the podcast page for episode notes, Dr. Nehmy's resources, and further reading on IADC. 0:00 - Amy introduces Dr. Tom and IADC therapy 2:34 - Tom Niemi's personal journey with grieving and after death communications 10:41 - Amy and Tom explain EMDR and its use in trauma therapy 18:20 - Dr. Nehmy details the IADC therapy process and origins 23:07 - What qualifies as an after death communication (ADC) 34:06 - Research and effectiveness of IADC for grief 45:45 - Acceptance, commonalities with NDEs DR. TOM NEHMY https://www.tomnehmy.com/https://www.amazon.com/Tom-Nehmy/e/B07Q5ZNVXC%3Fref=dbs_a_mng_rwt_scns_share JOIN MY COMMUNITY In The Space Between membership, you'll get access to LIVE quarterly Ask Amy Anything meetings (not offered anywhere else!), discounts on courses, special giveaways, and a place to connect with Amy and other like-minded people. You'll also get exclusive access to other behind-the-scenes goodness when you join! Click here to find out more --> https://shorturl.at/vVrwR Stay Connected: - Instagram - https://tinyurl.com/ysvafdwc- Facebook - https://tinyurl.com/yc3z48v9- YouTube - https://tinyurl.com/ywdsc9vt- Website - https://tinyurl.com/ydj949kt Life, Death & the Space Between Dr. Amy RobbinsExploring life, death, consciousness and what it all means. Put your preconceived notions aside as we explore life, death, consciousness and what it all means on Life, Death & the Space Between.**Brought to you by:Dr. Amy Robbins | Host, Executive ProducerPodcastize.net | Audio & Video Production | Hosted on Acast. See acast.com/privacy for more information.

This week's conversation with filmmaker Stephen Berkley left me in awe. His documentary Life with Ghosts reveals how his mother's crippling grief transformed when she began communicating with spirits. We explore automatic writing, induced after-death communication therapy (IADC), and why therapists MUST listen to clients' spiritual experiences. As a psychologist and medium, I'm passionate about bridging science and spirituality—especially for those drowning in loss. If you've ever felt a loved one's presence or questioned the afterlife, this episode is your validation. Plus: I'm launching a course for clinicians on spiritually informed therapy! Join me as we tear down the walls between grief and grace.00:00 Film "Life with Ghosts": Grief & the Afterlife 00:54 Podcast Intro & Stephen Berkley Welcome 02:03 Stephen's Mother: Complicated Grief Crisis 04:04 Ethel's Automatic Writing Revelation 06:09 Skepticism vs. Spiritual Connection 12:37 Grief Counselor's Dismissal of ADC 15:46 Scientific Backing: Dr. Dewi Rees Study 21:48 Induced After-Death Communication28:31 Stephen's Personal Spirit Communication Practices 33:40 Mainstreaming ADC: Research & Resistance 39:15 Therapists & Spiritual Openness41:48 Film Impact & PBS Release 44:33 Where to Watch & Closing TEPHEN BERKLEY· Watch Life with Ghosts: lifewithghosts.com· www.grief2growth.com In The Space Between membership, you'll get access to LIVE quarterly Ask Amy Anything meetings (not offered anywhere else!), discounts on courses, special giveaways, and a place to connect with Amy and other like-minded people. You'll also get exclusive access to other behind-the-scenes goodness when you join! Click here to find out more --> https://shorturl.at/vVrwR - Instagram - https://tinyurl.com/ysvafdwc- Facebook - https://tinyurl.com/yc3z48v9- YouTube - https://tinyurl.com/ywdsc9vt- Website - https://tinyurl.com/ydj949kt Life, Death & the Space Between Dr. Amy RobbinsExploring life, death, consciousness and what it all means. Put your preconceived notions aside as we explore life, death, consciousness and what it all mean**Dr. Amy Robbins | HostPodcastize.net | Audio & Video Production | Hosted on Acast. See acast.com/privacy for more information.

Arduino. Founded in Italy twenty years ago by a group of visionary educators and engineers, Arduino was born out of a desire to democratize electronics and make it accessible to everyone. Named after a bar in Ivrea, the platform started with hand-assembled circuit boards for students at the Interaction Design Institute Ivrea (IDII). The founders—Massimo Banzi, David Cuartielles, David Mellis, Tom Igoe, and Gianluca Martino—made key decisions to keep the hardware and software open-source, ensuring that anyone could learn, create, and innovate.   The result is… a world where anyone, regardless of their technical background, can create electronic projects that once seemed out of reach. This is the world that Arduino has made possible.   The significance of Arduino extends far beyond its technical specifications. It has lowered barriers of entry, making electronics affordable and accessible. Its massive open-source community fosters sharing and innovation, sparking the Maker movement and encouraging creation over consumption. Arduino has become a platform, bridging disciplines like art, design, engineering, and computer science, and enabling rapid prototyping. Its impact is felt in education, product development, and the philosophy of technology accessibility.   Arduino has inspired a global movement, empowering hobbyists, students, artists, and professionals to bring their ideas to life. It has influenced modern IoT and smart devices, proving that with the right tools, anyone can be an innovator. Arduino's choice of the AVR ATmega168 and later the ATmega328P microcontrollers was pivotal. These microcontrollers offered a balance of performance, cost, and ease of use, featuring 8-bit architecture, flash memory, SRAM, EEPROM, and built-in peripherals like timers, ADC, PWM, UART, SPI, and I2C. This made them ideal for a wide range of applications, from simple projects to complex prototypes.   What happens next is anybody's guess, but the frontiers spawned by the Shockley's and Moore's of the world, with their advanced educations and access to vast amounts of capital, are giving way to the kid in their bedroom, tinkering with a board and a laptop, intent on building a thing – turning their imagination into reality through simple advancements in integrated circuits, sensors, and open-source software.   How can Microchip Technology fuel the ethos of the Do-It-Yourself Maker movement?

While on site at the 2025 Spring Meeting of the ABA Antitrust Law Section, the Our Curious Amalgam team recorded interviews with senior competition agency enforcers from all over the world, including Germany and Portugal. In the first segment of this episode, James Hunsberger interviews Andreas Mundt, the President of Germany's Federal Cartel Office (Bundeskartellamt) and Chair of the Steering Group of the International Competition Network (ICN). Next, Jeny Maier's speaks with Nuno Cunha Rodrigues, the President of the Portuguese Competition Authority (AdC). Listen to this episode to hear what's been happening in their respective agencies and what makes them happy outside of competition law. With special guests: Andreas Mundt, President, Bundeskartellamt and Nuno Cunha Rodrigues, President, Autoridade da Concorrência Related Links: Federal Cartel Office of Germany (Bundeskartellamt) International Competition Network Portuguese Competition Authority (AdC) Hosted by: Alicia Downey, Downey Law LLC, James Hunsberger, Axinn, Veltrop & Harkrider LLP, and Jeny Maier, Axinn, Veltrop & Harkrider LLP